Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | IL6 | P05231 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13486325 | 0.94 | MET (0.40) | METBRD4S1PR2S1PR1S1PR3 | |
| SCHEMBL14386877 | 0.92 | BRD4 (0.42) | METBRD4S1PR2S1PR1S1PR3 | |
| SCHEMBL13486334 | 0.89 | BRD4 (0.40) | METBRD4S1PR2S1PR1S1PR3 | |
| SCHEMBL13486339 | 0.85 | MTNR1B (0.44) | METFAAH | |
| SCHEMBL3209421 | 0.84 | MAPT (0.45) | BRD4 | |
| SCHEMBL13486354 | 0.83 | MAPK8 (0.43) | METBRD4S1PR2S1PR1S1PR3 | |
| SCHEMBL3208999 | 0.82 | — | — | |
| SCHEMBL3201304 | 0.81 | MAPT (0.44) | BRD4 | |
| SCHEMBL3198331 | 0.81 | HTT (0.45) | — | |
| SCHEMBL13486329 | 0.79 | CYP3A4 (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| WO-2007135562-A2 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS S.A. (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | HPD, HPGDS, EPX | MET 2642/4885BRD4 2418/4885S1PR2 3036/4885 |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | MET 2642/4885BRD4 2418/4885S1PR2 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.